Marc Grundl

This inventor holds 19 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 10 EPO patents. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc Grundl. Retrieved from https://idiyas.com/inventor/marc-grundl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 6.5

ph-index = 13

Forward Citations = 285(Granted Patents)

Location History:

Biberach, DE (2012)
Biberach an der Riss, DE (2014 - 2024)

Company Filing History:

19 out of 1,562

Boehringer Ingelheim International Gmbh

patents

Years Active: 2012-2025

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12433897 - Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors (2025-10-07),

2. 12043625 - Pyridine derivatives with c-linked cyclic substituents as cGAS inhibitors (2024-07-23),

3. RE47636 - Substituted spirocycles (2019-10-07),

4. 10238633 - Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C (2019-03-26),

5. 9879026 - Substituted spirocycles (2018-01-30),

6. 9713606 - Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C (2017-07-25),

7. 9540373 - Substituted spirocycles (2017-01-10),

8. 9440960 - Substituted oxetanes and their use as inhibitors of cathepsin C (2016-09-13),

9. 9073869 - Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C (2015-07-07),

10. 8999975 - Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C (2015-04-07),

11. 8987249 - Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C (2015-03-24),

12. RE45323 - Substituted piperidines as CCR3 antagonists (2015-01-05),

13. 8889708 - Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C (2014-11-18),

14. 8883789 - Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors (2014-11-11),

15. 8877775 - Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C (2014-11-04),

Title: The Innovative Contributions of Marc Grundl

Introduction

Marc Grundl is a prominent inventor based in Biberach an der Riss, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cGAS inhibitors. With a total of 19 patents to his name, Grundl's work is recognized for its potential impact on medical science.

Latest Patents

Among his latest patents are innovative compounds such as pyridine derivatives with n-linked cyclic substituents and pyridine derivatives with c-linked cyclic substituents, both designed as cGAS inhibitors. These inventions relate to new proline derivatives that hold promise for therapeutic applications.

Career Highlights

Marc Grundl is currently employed at Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His role involves extensive research and development, focusing on creating novel therapeutic agents that can address unmet medical needs.

Collaborations

Throughout his career, Grundl has collaborated with notable colleagues, including Alexander Pautsch and Matthias Grauert. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new therapies.

Conclusion

Marc Grundl's contributions to the field of pharmaceuticals through his innovative patents and collaborative efforts highlight his importance as an inventor. His work continues to pave the way for advancements in medical science.

Profile summary based on public USPTO records.